<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924180</url>
  </required_header>
  <id_info>
    <org_study_id>DR180127 - GLEEPHEN</org_study_id>
    <secondary_id>2018-A03244-51</secondary_id>
    <nct_id>NCT03924180</nct_id>
  </id_info>
  <brief_title>Glytactin EfficiEncy in Non Treated Adult PHENylketonuria Patients</brief_title>
  <acronym>GLEEPHEN</acronym>
  <official_title>Glytactin EfficiEncy in Non Treated Adult PHENylketonuria Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSERM 1415-TOURS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phenylketonuria is the most common inherited metabolic disease in France and is screened for
      neonatal exposure. Management consists of a strict and restrictive hypoproteic diet and the
      intake of amino acid substitutes and dietary supplements free of phenylalanine.One of the
      major difficulties, which is the source of many treatment failures, is the inappetence of the
      amino acid supplements required during a strict hypoproteic diet. New formulations,
      Glycomacropeptides (GMP), have recently appeared and are considered more palatable than
      conventional amino acid mixtures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenylketonuria is the most common inherited metabolic disease in France and is screened for
      neonatal exposure. Management consists of a strict and restrictive hypoproteic diet and the
      intake of amino acid substitutes and dietary supplements free of phenylalanine. If the
      benefits of treatment are indisputable in children in terms of cognitive prognosis, this
      benefit is discussed once brain development is complete, especially as many adult patients
      are no longer treated. However, cognitive, neurological and reversible white matter disorders
      undergoing treatment are increasingly reported in adult phenylketonurics. As a result, recent
      European recommendations advocate the maintenance of life-long treatment. One of the major
      difficulties, which is the source of many treatment failures, is the inappetence of the amino
      acid supplements required during a strict hypoproteic diet. New formulations,
      Glycomacropeptides (GMP), have recently appeared and are considered more palatable than
      conventional mixtures.

      PRIMARY OBJECTIVE:

      Demonstrate a better metabolic balance under GMP treatment than a conventional amino acid
      mixture in adult phenylketonuric patients when resuming treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter randomized controlled trial performed in open and 2 parallel groups: &quot;GMP&quot; versus &quot;amino acids&quot; group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of phenylalaninemia on blotter</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of phenylalaninemia on blotter measured bi-monthly during the 6 months of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Therapeutic compliance measured after 3 months and 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of neuropsychological tests</measure>
    <time_frame>6 months</time_frame>
    <description>Neuropsychological tests measured after 3 months and 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI brain M0, M6 evolution</measure>
    <time_frame>6 months</time_frame>
    <description>MRI brain evolution between inclusion and 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone remodeling markers</measure>
    <time_frame>6 months</time_frame>
    <description>Bone remodeling markers at inclusion and 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of quality of life (PKU QoL score), mood (POMS test - Fillion 1999), at M0, M3, M6.</measure>
    <time_frame>6 months</time_frame>
    <description>Evolution of quality of life scores at inclusion, 3 months and 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional and clinical markers evaluated at inclusion and 6 months of treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Evolution of nutritional and clinical markers at inclusion and 6 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tolerance at M3 and M6</measure>
    <time_frame>6 months</time_frame>
    <description>Evolution of Gastrointestinal tolerance after 3 months and 6 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Adult Phenylketonuria Non Treated Patients</condition>
  <arm_group>
    <arm_group_label>GMP - Dietary Supplement for PKU patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycomacropeptides -GMP Glytactin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control -Amino acids mixtures</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mixtures of conventional amino acids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement for PKU patients</intervention_name>
    <description>For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.</description>
    <arm_group_label>Control -Amino acids mixtures</arm_group_label>
    <arm_group_label>GMP - Dietary Supplement for PKU patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phenylketonuric patient diagnosed in neonatal screening

          -  Patient with Phenylalaninemia ≥ 900μmol / L on blotter made during the screening
             period (or average blotting results ≥900 μmol / L if several blots made during the
             screening period)

          -  Untreated patient: not taking any amino acid supplement for his PKU, regardless of
             diet

        Exclusion Criteria:

          -  Protected patient: court bail, curatorship, guardianship

          -  Patient with concomitant diseases / conditions that may compromise the study, at the
             discretion of the investigator

          -  Participated in a clinical trial or trial to evaluate PKU foods or treatments in the
             last 7 days prior to inclusion or planned during the next 6 months

          -  Participation in an interventional study with health products during the next 6 months

          -  Pregnancy project within 6 months, pre-conception diet, pregnancy or breastfeeding

          -  Refusal to consume only validated complements for the protocol

          -  Phenylketonuria undergoing treatment with BH4

          -  Allergy to the product under study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrien BIGOT, MD-PHD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of TOURS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrien BIGOT, MD-PHD</last_name>
    <phone>+33234389584</phone>
    <email>adrien.bigot@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wiebe de JONG, MSc</last_name>
    <phone>+33247474680</phone>
    <email>w.dejong@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU-Hôpital Bretonneau - Service de Médecine Interne-Nutrition</name>
      <address>
        <city>Tours</city>
        <state>Centre</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maeva DIEU</last_name>
      <phone>+33218370806</phone>
      <email>m.dieu@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>François MAILLOT, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU-ANGERS -Médecine Interne</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU du Morvan-Département de Pédiatrie et génétique médicale,</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant-Centre de Référence des Maladies Héréditaires du Métabolisme de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de LILLE-Hôpital Claude HURIEZ-Service d'Endocrinologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU-Service de Réanimation Pédiatrique / Néonatalogie, Consultation spécialisée en Maladies Héréditaires du Métabolisme</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice KÜSTER, MD-PHD</last_name>
      <phone>0240087678</phone>
      <email>alice.kuster@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Alice KÜSTER, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU-RENNES-Hôpital Sud-Service de Génétique-Clinique</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amino acid</keyword>
  <keyword>GMP</keyword>
  <keyword>PKU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

